Brief: Portage Biotech resumes enrollment in final group of its early-stage study for its cancer treatments
12/03/2025 14:15
March 12 (Reuters) - Portage Biotech Inc PRTG.O: PORTAGE BIOTECH RESUMES ENROLLMENT IN FINAL COHORT OF DOSE ESCALATION FOR PORT-6 IN ADPORT-601 TRIAL PORTAGE BIOTECH : ENCOURAGING SAFETY PROFILE SUPPORTS PROGRESSION TOWARD FIRST DUAL-ADMINISTRATION OF SELECTIVE A2A AND A2B ANTAGONISTS IN PATIENTS Further company coverage: PRTG.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alpha Compute
See all newsAlpha Compute Corp expected to post a loss of $3.50 a share - Earnings Preview
NASDAQ RESUMED AT 10:18 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:13 AM
Brief: Alpha Compute Signs Binding Gpu Contract, Leasing ALPHA-03 Cluster Under Four-Year, $81.7 Million Agreement In Its Missouri Superintelligence Factory
Alpha Compute Corp expected to post a loss of $3.50 a share - Earnings Preview